How Much Does Vaginal Estradiol Cost in Utah in 2026?

Retail and Cash-Pay Pricing Across Utah

The average cash-pay price for vaginal estradiol in Utah sits at roughly $120 per month in 2026. That figure reflects what patients without insurance pay at chain and independent pharmacies statewide, from Salt Lake City to St. George. The manufacturer list price, by contrast, hovers around $280 per month for branded formulations.

Pricing varies by formulation and pharmacy. Estrace cream (estradiol vaginal cream, 0.01%) tends to carry the highest list price. Vagifem and Yuvafem (estradiol vaginal tablets, 10 mcg) fall slightly lower on the price spectrum, though generic versions of the vaginal tablet have driven meaningful savings since generic entry. The Estring vaginal ring (7.5 mcg/24 hours, 90-day duration) presents a higher per-unit cost but a lower effective monthly price when divided across its three-month lifespan.

A 2016 Cochrane systematic review (N=30 trials, 6,235 women) found no significant difference in efficacy between low-dose vaginal estradiol creams, tablets, and rings for treating vaginal atrophy symptoms 1. That clinical equivalence matters for Utah patients making cost-driven decisions. If a $280-per-month cream delivers the same symptom relief as a $90-per-month generic tablet, the choice becomes straightforward.

GoodRx and similar discount platforms list Utah-specific prices that range from $38 to $145 depending on formulation, dose, and pharmacy location. Costco pharmacies in Salt Lake City and Orem tend to price generic estradiol vaginal cream at the lower end of that range. Walmart and Smith's pharmacies cluster near the median.

Utah Medicaid Coverage: What's Excluded and Why

Utah Medicaid does not cover vaginal estradiol for genitourinary syndrome of menopause. This exclusion affects an estimated 180,000 postmenopausal women enrolled in Medicaid or Medicaid-expansion plans in the state, according to Utah Department of Health enrollment data.

The exclusion is not unique to Utah. Medicaid drug formularies in many states classify vaginal estrogen as a "comfort" medication rather than a medically necessary treatment, despite the North American Menopause Society (NAMS) 2020 position statement recommending low-dose vaginal estrogen as first-line therapy for GSM. Dr. Stephanie Faubion, NAMS Medical Director, has stated: "Low-dose vaginal estrogen is the most effective treatment for genitourinary syndrome of menopause, and barriers to access cause real harm to women's quality of life."

For Utah Medicaid enrollees, the practical options include: filing a prior authorization appeal citing medical necessity (success rates remain low for this indication), switching to a non-hormonal alternative like ospemifene (Osphena), which may have different formulary status, or accessing compounded estradiol through a 503A pharmacy, which falls outside the Medicaid drug benefit entirely.

The Affordable Care Act requires marketplace plans to cover FDA-approved contraceptives without cost-sharing, but vaginal estradiol prescribed for GSM does not fall under that mandate. This distinction catches many Utah patients off guard.

Insurance Coverage on Commercial Plans

Most commercial insurance plans operating in Utah do cover FDA-approved vaginal estradiol formulations, though coverage terms vary widely. SelectHealth (the largest Utah-based insurer, affiliated with Intermountain Health), PEHP (Public Employees Health Program), and national carriers like Blue Cross Blue Shield, UnitedHealthcare, and Cigna each maintain their own formulary placement.

SelectHealth typically places generic vaginal estradiol tablets at Tier 2 (preferred brand) with copays ranging from $25 to $50. Brand-name Estrace cream often lands at Tier 3 (non-preferred), pushing copays to $50 to $75. The vaginal ring may require step therapy documentation showing that a cream or tablet was tried first.

Prior authorization is the most common barrier. Insurers in Utah frequently require documentation of: a confirmed GSM or vulvovaginal atrophy diagnosis, failure of or contraindication to non-hormonal moisturizers, and absence of contraindications including a history of estrogen-receptor-positive breast cancer. A 2019 JAMA Internal Medicine analysis found that prior authorization requirements for vaginal estrogen delayed treatment initiation by a median of 14 days across commercial plans 2.

PEHP, which covers state employees and their dependents, has a somewhat more favorable formulary. Generic estradiol vaginal cream and tablets both sit at Tier 2 with a $20 copay after deductible. The ring requires a Tier 3 exception request.

Compounded Vaginal Estradiol in Utah

Compounded vaginal estradiol is legal in Utah through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidance from the FDA's 503A framework. Utah has roughly 40 licensed 503A pharmacies, concentrated along the Wasatch Front.

The economics of compounded vaginal estradiol differ from retail. Several telehealth platforms now offer membership models where patients pay a flat monthly fee ($0 to $30) that includes the compounded medication, shipping, and provider consultations. The estradiol itself, compounded as a vaginal cream in concentrations typically ranging from 0.01% to 0.03%, costs these pharmacies a fraction of the branded equivalent to produce.

A few caveats apply. Compounded drugs are not FDA-approved and do not undergo the same stability, potency, and bioavailability testing as commercially manufactured products. The American College of Obstetricians and Gynecologists (ACOG) recommends FDA-approved formulations as first choice, with compounded versions reserved for patients who need specific dose adjustments or have allergies to inactive ingredients in commercial products.

Dr. JoAnn Pinkerton, former NAMS Executive Director, has noted: "When an FDA-approved vaginal estradiol product is available and affordable, it should be preferred over compounded versions because of the regulatory oversight ensuring consistent dosing and purity."

Utah law does not restrict which licensed prescribers can order compounded hormones. Both physicians and advanced practice clinicians (nurse practitioners, physician assistants) with prescriptive authority may prescribe compounded vaginal estradiol. The prescription must be patient-specific under 503A rules; bulk manufacturing without individual prescriptions falls under the stricter 503B outsourcing facility requirements.

Telehealth Access for Utah Patients

Utah permits telehealth prescribing of vaginal estradiol. The state's Telehealth Act (Utah Code 26-60) allows licensed providers to prescribe hormonal medications via audio-video consultation without an in-person exam, provided the standard of care is met.

This legal framework has opened access for patients in rural Utah counties where OB-GYN availability is limited. Beaver, Daggett, Garfield, Kane, Piute, Rich, and Wayne counties each have zero practicing gynecologists. Telehealth removes the geographic barrier entirely.

Several national telehealth platforms serve Utah patients for vaginal estradiol prescriptions. Pricing models vary: some charge a consultation fee ($49 to $99) plus the cost of medication, while membership-based platforms bundle the consultation and compounded medication into a single monthly subscription. HealthRX offers Utah patients access to prescribed vaginal estradiol through a streamlined telehealth model that includes clinician evaluation and ongoing monitoring.

The telehealth visit itself typically lasts 15 to 25 minutes. Clinicians review symptoms (vaginal dryness, dyspareunia, urinary urgency), medical history, contraindications, and breast cancer screening status before prescribing. Follow-up visits are recommended at 4 to 12 weeks to assess symptom response, per the Endocrine Society's 2019 clinical practice guideline on menopause management [3].

How to Reduce Your Cost in Utah

Multiple strategies can bring the price of vaginal estradiol below the $120 average. Here they are, ranked by typical savings.

Generic substitution. Switching from branded Estrace or Vagifem to their generic equivalents saves 40% to 60% at most Utah pharmacies. Generic estradiol vaginal cream is available, and generic estradiol vaginal tablets (marketed as Yuvafem or simply "estradiol vaginal tablets") have been on the market since 2016.

Pharmacy shopping. Pricing differences between Utah pharmacies for the same generic product can exceed $80 per month. Costco, which does not require a membership for pharmacy purchases, consistently offers the lowest cash prices in Utah metro areas. Independent pharmacies sometimes match or beat chain pricing when asked directly.

Manufacturer savings cards. Allergan (now AbbVie) has periodically offered copay cards for Estrace cream that reduce out-of-pocket costs to $25 to $35 per fill for commercially insured patients. These cards do not apply to government-funded insurance (Medicaid, Medicare Part D, Tricare). Availability and terms change frequently, so patients should verify current offers at the manufacturer's website.

Compounded alternatives. As discussed above, 503A compounding pharmacies in Utah can produce vaginal estradiol cream at significantly lower cost. For uninsured patients, this route often represents the greatest absolute savings.

Patient assistance programs. AbbVie's patient assistance program covers Estrace cream for patients meeting income criteria (typically below 200% of the federal poverty level). Application requires proof of income and a prescription from a licensed provider.

GoodRx and RxSaver coupons. These platforms aggregate negotiated rates from pharmacy benefit managers. In Utah, GoodRx coupons frequently bring generic vaginal estradiol cream below $50 per month at CVS, Walgreens, and Smith's.

Clinical Dosing and What Affects Your Monthly Spend

The prescribed dosing regimen directly affects monthly cost. Vaginal estradiol cream is typically started at 1 gram intravaginally daily for two weeks, then reduced to 1 gram twice weekly for maintenance, per FDA-approved labeling. A 42.5-gram tube of estradiol vaginal cream contains approximately 42 doses at 1 gram each. On a twice-weekly maintenance schedule, one tube lasts roughly 5 months. That changes the effective monthly cost dramatically.

At a cash price of $120 per tube, the effective monthly cost on maintenance dosing drops to approximately $24 per month. Patients and pharmacists sometimes miscalculate costs based on a 30-day supply assumption when the actual tube lasts far longer on maintenance dosing.

Vaginal estradiol tablets (10 mcg) follow the same pattern: daily for two weeks, then twice weekly. A box of 18 tablets at twice-weekly dosing covers about 9 weeks. The vaginal ring lasts 90 days per unit, making its per-month cost calculation the most straightforward.

The Cochrane review mentioned earlier confirmed that symptom improvement with low-dose vaginal estradiol typically begins within 2 to 4 weeks, with maximum benefit at 12 weeks 1. A 2002 randomized trial (N=159) in Obstetrics & Gynecology found that the 10 mcg vaginal tablet improved vaginal maturation index by 29.7 percentage points versus 7.6 for placebo at 12 weeks 4.

Patients should factor in the cost of follow-up visits. A single telehealth follow-up runs $0 to $75 depending on the platform and insurance status. In-office visits with a Utah gynecologist average $150 to $250 for an established patient visit without insurance.

Safety Considerations That Affect Prescribing

The FDA's boxed warning on estrogen products applies to vaginal estradiol, though the clinical risk profile for low-dose vaginal formulations differs significantly from systemic estrogen therapy. A 2020 BMJ cohort study (N=896,996 women) found no statistically significant increase in cardiovascular events, venous thromboembolism, or breast cancer with vaginal estrogen use over a median 4.3-year follow-up 5.

The Endocrine Society's 2019 guideline states that low-dose vaginal estrogen "does not raise serum estradiol levels above the normal postmenopausal range" and can be considered even in women with a history of estrogen-sensitive cancers after consultation with their oncologist 3. This safety profile means fewer restrictions on long-term use, which affects the total cost-of-treatment calculation for Utah patients.

Systemic absorption with low-dose vaginal estradiol is minimal. Serum estradiol levels remain below 20 pg/mL (the upper limit of the postmenopausal range) with all three delivery forms at standard doses, according to pharmacokinetic data in the FDA product labels. This pharmacokinetic reality supports the argument for exempting low-dose vaginal estrogen from the same prescribing restrictions applied to systemic hormone therapy.